Skip to content

Price / book at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
5.9×-1.7×
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
27.8×-20.7×
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
3.5×+0.3×
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
3.6×-5.6×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
3.1×+1.3×
Immunome logo
ImmunomeIMNM
4.2×+2.3×

Other financials

Income statement

See full
Operating income-$125.1M-119%
Net income-$121.0M-134%
EPS (diluted)-$1.69-109%

Balance sheet

See full
Cash & equivalents$114.4M+108%
Total debt$75.0M+37.8%
Total equity$499.7M-6.6%
Total assets$621.7M+1.9%

Cash flow

See full
Operating cash flow-$106.5M-95.8%
CapEx$23.0K-87.7%
Free cash flow-$106.5M-95.1%

Valuation

See full
Market cap$2.74B+87.5%
Enterprise value$2.7B+85.0%

Returns & leverage

See full
Return on equity-71.3%+296pp
Debt / equity0.2×0.0×
Current ratio13.6×-14.0×

Where this comes from

Calculated from Vera Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vera Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vera Therapeutics's price / book?
Vera Therapeutics (VERA) reported price / book of 5.7× in Q1 2026.
How has Vera Therapeutics's price / book changed year-over-year?
Vera Therapeutics's price / book increased by 100.7% year-over-year, from 2.9× to 5.7×.
What is the long-term trend for Vera Therapeutics's price / book?
Over 4 years (2021 to 2025), Vera Therapeutics's price / book has grown at a -10.6% compound annual growth rate (CAGR), from 9.3× to 5.9×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.